How Should COVID-19 Vaccines be Distributed between the Global North and South? A Discrete Choice Experiment in Six European Countries

3 4

JI Steinert[§]*, DPhil, TUM School of Social Sciences & Technology and TUM School of
 Medicine, Richard-Wagner Str. 1, 80333 München, Technical University of Munich, Munich,

- Germany, janina.steinert@tum.de, phone: +4915784562543, Twitter: @jisteinert
- 9 H Sternberg*, MSc, TUM School of Social Sciences & Technology, Technical University of
 10 Munich, Munich, Germany
 11
- 12 GA Veltri, PhD, University of Trento, Trento, Italy13
- 14 **T Büthe,** PhD, TUM School of Social Sciences & Technology and TUM School of
- 15 Management, Technical University of Munich, Munich, Germany; Kenan Institute for Ethics,
- 16 Duke University
- 18 [§]corresponding author
- 19 **joint first authors*

20 Abstract

Background: The global distribution of COVID-19 vaccinations remains highly unequal. We
examine public preferences in six European countries regarding the allocation of COVID-19
vaccines between the Global South and Global North.

24

Methods: We conducted online discrete choice experiments with adult participants in France (n=766), Germany (n=1964), Italy (n=767), Poland (n=670), Spain (n=925), and Sweden (n=938). Respondents were asked to decide which one of two candidates, who varied along four attributes: age, mortality risk, employment, and living in a low- or high-income country, should receive the vaccine first. We analysed the relevance of each attribute in allocation decisions using a conditional logit regression.

31

32 Results: Across countries, respondents selected candidates with a high mortality and infection 33 risk, irrespective of whether the candidate lived in their own country. All else equal, 34 respondents in Italy, France, Spain, and Sweden gave priority to a candidate from a low-income 35 country, whereas German respondents were significantly more likely to choose the candidate 36 from their own country. Female, younger, and more educated respondents were more 37 favourable of an equitable vaccine distribution.

- 38
- 39 Conclusions: Given these preferences for global solidarity, European governments should40 promote vaccine transfers to poorer world regions.
- 41

Funding: Funding was provided by the European Union's Horizon H2020 research and
innovation programme under grant agreement 101016233 (PERISCOPE).

- 44
- 45 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

46 Introduction

47 In his opening speech to address the United Nations General Assembly in September 2021, 48 Secretary General António Guterres expressed stark discontent with the highly unequal global distribution of COVID-19 vaccines: "A majority of the wealthier world is vaccinated. Over 90 49 50 percent of Africans are still waiting for their first dose. This is a moral indictment of the state of our world. It is an obscenity." (UN Secretary General, 2021). At the time of writing, only 51 52 10% of citizens in low-income countries have received at least one dose of a COVID-19 vaccine, while more than 80% of available doses have been allocated to people in high-income 53 54 countries.(Padma, 2021) This blatant inequity in access to COVID-19 vaccines is partly a consequence of widespread vaccine nationalism in high-income countries, including the 55 stockpiling of vaccine doses for their own citizens.(Harman et al., 2021; Herzog et al., 2021; 56 Wagner et al., 2021) 57

58

To ensure "fair and equitable access" to COVID-19 vaccines for all countries, the World Health 59 Organisation (WHO), the Vaccine Alliance (Gavi), and the Coalition for Epidemic 60 61 Preparedness Innovations (CEPI) formed a multilateral initiative named "COVID-19 Vaccines Global Access" (COVAX).(Herzog et al., 2021) However, several governments have resorted 62 to making bilateral purchasing agreements with vaccine manufacturers outside of COVAX. 63 which has substantially weakened the initiatives' collective purchasing power.(Kim, 2021; 64 Wouters et al., 2021) Moreover, recent estimates published by "Think Global Health" suggest 65 66 that only a small fraction of the promised vaccine doses have actually reached people in lowincome countries. The WHO's pledges for a more equitable COVID-19 vaccine distribution 67 have not been fulfilled. 68

70 Ramping up global COVID-19 vaccination rates is imperative for three reasons. From an 71 ethical perspective, unequal access to vaccination leads to high rates of transmission, severe 72 infections, and deaths in those parts of the world where health care capacity is the lowest. This 73 aggravates existing health inequities between the Global South and North.(Godlee, 2021; Katz 74 et al., 2021; Krause et al., 2021; Wagner et al., 2021) In addition, achieving a more equitable vaccine distribution would have utilitarian benefits: A recent modeling study compared two 75 76 hypothetical scenarios - one in which the 50 richest countries used all available vaccines and one in which vaccines were allocated to all countries proportionally to their population size -77 78 finding that the former scenario would lead to twice as many COVID-19 deaths.(Herzog et al., 79 2021) Second, there are compelling economic arguments in favour of equitable vaccine distribution: The RAND Corporation estimates that constrained access to COVID-19 vaccines 80 81 in low- and middle-income countries (LMICs) would reduce the global GDP by US\$ 153 82 billion each year, including a loss of US\$ 56 billion in the European Union and United States 83 combined.(Hafner et al., 2020) Put differently, every US\$ 1 spent on supplying vaccines to 84 LMICs would yield a return of US\$ 4.8.(Hafner et al., 2020) Third, alleviating global asymmetries in COVID-19 vaccine coverage is warranted for virologic reasons. Unmitigated 85 86 COVID-19 transmissions in some parts of the world will create evolutionary reservoirs from which new SARS-CoV-2 variants could arise, increasing the risk of immune escape - for both 87 vaccine-induced and natural immunity - and of other phenotypic changes that could lead to 88 89 greater virulence.(Saad-Roy et al., 2021; Telenti et al., 2021; van Oosterhout et al., 2021; Wagner et al., 2021) As WHO Director General Tedros Adhanom Ghebreyesus put it: "none 90 91 of us will be safe until everyone is safe".(UN Secretary General, 2021b)

92

93 Decision-makers in high-income countries are incentivised to engage in vaccine nationalism if
94 there is limited public support for giving COVID-19 vaccines to poorer regions of the

world.(Clarke et al., 2021) Public opinion can be affected by populist rhetoric from nationalist
parties, portraying vaccine donations to the Global South as a lack of patriotism. Governments
will likely only donate vaccines or actively participate in international vaccine alliances such
as COVAX if they do not expect to pay a price at the ballot box. A thorough understanding of
public preferences for the global distribution of COVID-19 vaccines is therefore paramount.

100

101 Recent empirical literature has explored public preferences for the allocation of COVID-19 102 vaccines. A majority of these studies examined public opinion on prioritisation within high-103 income countries and when COVID-19 vaccine availability was still heavily constrained in 104 those countries.(Duch et al., 2021; Gollust et al., 2020; Knotz et al., 2021; Luyten et al., 2020; 105 Persad et al., 2021; Reeskens et al., 2021; Sprengholz et al., 2021) Based on data from online 106 surveys and survey experiments, the studies revealed substantial public support for prioritising 107 frontline healthcare workers and clinically vulnerable groups. (Duch et al., 2021; Persad et al., 108 2021) To our knowledge, only four studies to date have examined individuals' preferences on 109 the distribution of COVID-19 vaccines across national borders.(Clarke et al., 2021; Guidry et 110 al., 2021; Klumpp et al., 2021; Vanhuysse et al., 2021) One online survey conducted in seven 111 high-income countries found that around 50% of participants generally supported global 112 allocation schemes that would give priority to the countries that could not afford to purchase 113 vaccines.(Clarke et al., 2021) Another survey conducted in the US found that 40% of 114 respondents were in favour of donating at least 10% of the nationally purchased vaccines to 115 poorer countries. Support was less pronounced among older respondents – a group that is at 116 greater risk of severe disease progression if infected.(Guidry et al., 2021)

117

A survey conducted in Germany asked participants to choose between different options for
international agreements and alliances on the distribution of COVID-19 vaccines, which varied

by (i) countries joining the agreement, (ii) distribution rules, and (iii) cost per German
household. The authors found that participants displayed a strong preference for an alliance
exclusively composed of EU states. More importantly, the authors found that participants were
more supportive of vaccine alliances if the national cost of participation was lower and national
vaccine coverage higher, suggesting that participants' preferences were significantly shaped
by self-interest.(Vanhuysse et al., 2021)

126

127 In contrast, in a discrete choice experiment conducted in Germany and the US, participants in 128 both countries expressed a strong preference for prioritising vaccine allocation to countries 129 with a higher number of COVID-19 deaths and fewer intensive care unit beds, even when they 130 were asked to imagine that they or a vulnerable family member were still waiting for the 131 COVID-19 vaccine.(Klumpp et al., 2021) Notably, no previous study to date has exclusively 132 sampled participants who were still waiting for their first COVID-19 vaccine dose when 133 participating in the survey experiment.

134

135 In this paper, we analyse new experimental evidence from six EU countries on citizens' preferences for the distribution of COVID-19 vaccines between the Global South and North. 136 137 We advance the literature in three ways. First, by covering six countries, we implement the 138 largest survey experiment on international vaccine allocation preferences to date and are thus 139 able to examine differences in citizens' preferences across EU member states. Second, we 140 conduct a discrete choice experiment among participants who are themselves not yet 141 vaccinated, asking them to allocate a COVID-19 vaccine to either a person in their own country 142 or to a person in a country in the Global South. This places specific salience on the notion that 143 donating a vaccine dose to a person in the Global South might mean sacrificing one's own dose or that of a fellow citizen, thus leveraging self-interest-based and nationalistic considerations. 144

145 Third, we specifically examine heterogeneity in participants' preferences along key 146 sociodemographic characteristics. Policymakers can use these insights to anticipate which 147 population groups will be most and least supportive of COVID-19 vaccine donations.

148 **Results**

149 Sample characteristics

150

A total of 6,030 eligible participants across all six countries completed the DCE. We excluded 151 152 participants who did not reply to all of the eight choice tasks in the DCE. To that end, attrition 153 across choice tasks ranged from 0% in Germany and Sweden, roughly 10% in France, Poland and Spain, to almost 15% in Italy. Table 1 presents socioeconomic characteristics of 154 155 participants in each country. The German sample shows higher proportions of (i) older 156 participants (age groups 55-64 and 65+ years), (ii) less educated participants, and (iii) 157 participants with an increased risk of a severe COVID-19 infection. Cross-country differences 158 in the sample compositions and deviations from the census statistics are probably linked to the 159 timing of the survey launch and the vaccination progress in each country. The German survey was launched earlier, when a higher number of older people were not yet eligible for the 160 161 COVID-19 vaccination and therefore were eligible to participate in the survey.

103
103

Table 1. Socio-demographic characteristics

	Germany	Spain	Italy	France	Poland	Sweden
Female	938	471	363	376	365	465
	(47.76%)	(50.92%)	(47.33%)	(49.09%)	(54.48%)	(49.57%)
Age group						
18-24	148	111	107	106	185	104
	(7.54%)	(12.00%)	(13.95%)	(13.84%)	(27.61%)	(11.09%)
25-34	279	259	163	191	179	268
	(14.21%)	(28.00%)	(21.25%)	(24.93%)	(26.72%)	(28.57%)
35-44	361	307	162	217	152	281
	(18.38%)	(33.19)	(21.12%)	(28.33%)	(22.69%)	(29.96%)
45-54	376	193	177	236	105	179
	(19.14%)	(20.86)	(23.08%)	(30.81%)	(15.67%)	(19.08%)
55-64	484	52	130	16	41	97
	(24.64%)	(5.62%)	(16.95%)	(2.09%)	(6.12%)	(10.34%)
65+	316	3	4	0	8	9
	(16.09%)	(0.32%)	(0.52%)	(0%)	(1.19%)	(0.96%)
Education						
Primary	631	3	27	9	17	40
	(32.13%)	(0.32%)	(3.52%)	(1.17%)	(2.54%)	(4.26%)
Secondary	622	171	141	79	130	311
	(31.67%)	(18.49%)	(18.38%)	(10.31%)	(19.40%)	(33.16%)
Higher	359	264	353	301	337	159
	(18.28%)	(28.54%)	(46.02%)	(39.30%)	(50.30%)	(16.95%)
University degree	352	487	222	377	186	428
	(17.92%)	(52.56%)	(28.94%)	(49.22%)	(27.76%)	(45.63%)
Employed	1,204	647	480	579	460	753
	(61.30%)	(69.95%)	(62.58%)	(75.59%)	(68.66%)	(80.28%)
CV-19 high-risk group	1,041	255	204	219	256	190
	(53.00%)	(27.57%)	(26.60%)	(28.59%)	(38.21%)	(20.26%)
Elevated CV-19 threat perception	1,056	491	434	349	222	462
	(53.88%)	(53.08%)	(58.41%)	(45.56%)	(33.13%)	(49.25%)
Observations	1964	925	767	766	670	938

Notes: The table shows sample characteristics of participants by country, reporting both the absolute number of participants as well as the relative proportion of the respective characteristic prevalent in the sample. 'CV-19' denotes 'COVID-19'.

169 Discrete Choice Experiment

170

171 Table 2 summarises results for the main effects model, which shows, separately for each 172 country, the impacts of the four attributes and levels on a candidate's likelihood of being chosen 173 by the respondent to receive the COVID-19 vaccine first. In France, Italy, Spain, and Sweden, 174 respondents, on average, chose the hypothetical candidate from the Global South over the 175 hypothetical candidate from their own country to receive the vaccine first (Spain: OR: 1.79, 95% CI: 1.55-2.06; Italy: OR: 1.74, 95% CI: 1.50-2.01; Sweden: OR: 1.43, 95% CI: 1.24-1.65; 176 177 France: OR: 1.37, 95% CI: 1.18-1.59; all p-values<0.001). For German respondents, we 178 observe the opposite pattern: candidates from the Global South had significantly lower odds of 179 being chosen to receive the vaccine (OR: 0.69, 95% CI: 0.62-0.76, p-value<0.001). In Poland, 180 a candidate's country of residence neither increased nor decreased the odds of being chosen to 181 receive the vaccine (OR: 0.99, 95% CI: 0.86-1.15).

182

For the attribute of COVID-19 mortality risk, we observe a similar pattern in all surveyed countries: The odds of being chosen to receive the vaccine were between two and almost six times higher for a candidate with an increased COVID-19 mortality risk, relative to a candidate with an average risk. The effect was even more pronounced for a candidate with a strongly increased mortality risk (ranging from OR: 4.35, 95% CI: 3.65-5.19 in Poland to OR: 14.20, 95% CI: 11.75-17.17 in Sweden; all p-values<0.001).

189

For employment status and age, we also observed largely similar patterns across countries: First, employed candidates who lost income due to the pandemic and candidates who were employed in essential services exhibited were significantly more likely to be chosen to receive the vaccine when compared to unemployed candidates. Second, in all countries, 40-year-old

194 candidates had slightly higher odds of being chosen to receive the vaccine than 20- or 60-year-195 old candidates.

196

197 Figure 1 illustrates the results of the heterogeneity analysis that was pooled across countries 198 (see Tables S2-3 for exact coefficients by subgroup and interaction terms). The odds of 199 choosing the candidate from the Global South rather than the candidate from the respondents' 200 own country were significantly higher for female (OR of interaction: 1.22, 95% CI: 1.10-1.36, 201 p-value<0.001) and more educated (OR of interaction: 1.63, 95% CI: 1.46-1.82, p-202 value<0.001) respondents, and significantly lower for older respondents (above 45 years) (OR 203 of interaction: 0.68, 95% CI: 0.61-0.76, p-value<0.001). In contrast, respondents who were 204 themselves at high risk of a severe COVID-19 disease progression were significantly less 205 supportive of distributing the COVID-19 vaccine to a candidate from the Global South (OR of 206 interaction: 0.70, 95% CI: 0.63-0.78, p-value<0.001). In the subgroup of employed 207 respondents, the odds of distributing the vaccine to a candidate in the Global South were 208 slightly lower than in the subgroup of unemployed respondents (OR of interaction: 0.89, 95%) 209 CI: 0.80-1,00, p-value=0.045). The degree of COVID-19 threat perception did not seem to 210 significantly affect respondents' distribution preferences (OR of interaction: 1.10, 95% CI: 0.99-1.22, p-value=0.071). 211

Outcome: Choosing the respectiv	ve candidate to re	eceive the vacc	ine			
	Germany	Spain	Italy	France	Poland	Sweden
	(1)	(2)	(3)	(4)	(5)	(6)
Age					-	
20 years			Reference	category		
40 years	1.39***	1.25***	1.16***	1.15***	1.08*	1.13***
	[1.33,1.45]	[1.17,1.33]	[1.09,1.22]	[1.08,1.22]	[1.02,1.14]	[1.06,1.20]
60 years	0.87***	0.85***	0.88***	0.87***	0.85***	0.77***
	[0.83,0.90]	[0.80,0.91]	[0.84,0.94]	[0.82,0.93]	[0.80,0.91]	[0.73,0.82]
80 years	0.81***	1.23**	1.12	0.59***	0.94	0.70***
	[0.73,0.90]	[1.06,1.43]	[0.94,1.33]	[0.50,0.69]	[0.78,1.13]	[0.61,0.81]
COVID-19 mortality risk						
Average	Reference category					
Increased	5.63***	3.05***	2.27***	4.54***	2.40***	5.67***
	[5.13,6.19]	[2.66,3.50]	[1.96,2.64]	[3.88,5.31]	[2.07,2.79]	[4.91,6.56]
Strongly increased	13.23***	9.68***	4.36***	9.04***	4.35***	14.20***
	[11.64,15.03]	[8.12,11.53]	[3.69,5.15]	[7.50,10.91]	[3.65,5.19]	[11.75,17.1 7]
Employment situation						,]
Not employed	Reference category					
Employed (guaranteed income)	1.30***	0.79**	1.14	1.04	1.06	1.00
	[1.18,1.42]	[0.68,0.92]	[0.99,1.32]	[0.89,1.22]	[0.91,1.24]	[0.87,1.16]
Employed (income losses)	2.37***	1.91***	1.67***	1.65***	1.36***	1.73***
	[2.19,2.56]	[1.71,2.13]	[1.49,1.87]	[1.47,1.86]	[1.21,1.53]	[1.54,1.94]
Essential services	6.01***	4.05***	2.27***	2.74***	1.88***	4.22***
	[5.38,6.72]	[3.50,4.70]	[1.98,2.59]	[2.33,3.22]	[1.65,2.15]	[3.57,4.99]
Country of residence						
Respondents' country	Reference category					
Global South	0.69***	1.79***	1.74***	1.37***	0.99	1.43***
	[0.62,0.76]	[1.55,2.06]	[1.50,2.01]	[1.18,1.59]	[0.86,1.15]	[1.24,1.65]
Log likelihood	-14428.91	-7090.45	-6541.07	-5994.74	-5860.07	-6875.04
AIC	28875.82	14198.89	13100.14	12007.48	11738.15	13768.07
BIC	28951.02	14267.31	13166.88	12074.21	11803.67	13836.62
Pseudo R^2	0.22	0.19	0.10	0.17	0.08	0.23

Table 2. Main attribute effects by country

Observations

215

Notes: Coefficients are odds ratios based on conditional logit estimations with standard errors clustered at the individual level. Results to be interpreted relative to the indicated reference category. 95% confidence intervals in brackets. * p < 0.05, ** p < 0.01, *** p < 0.001. Sample sizes reflect the eight choice tasks performed by each respondent.

223 Figure S3 and Tables S4-9 summarise the extent to which these patterns prevail in each country. 224 The heterogeneities we identify were strongest in the German, Spanish, and Swedish samples. 225 In the French and Italian sample, these patterns were prevalent, too, but not statistically 226 significant. Interestingly, in terms of age, we found that older participants were relatively more 227 supportive of distributing the vaccine to a candidate from the Global South in both countries. 228 In the Italian sample, this effect was even statistically significant (OR of interaction: 1.34, 95% 229 CI: 1.00-1.78, p-value=0.049). In the Polish survey, heterogeneity patterns were less clear, and 230 we observed an opposite effect for educational attainment, with less educated respondents 231 showing more pronounced preferences for an equitable vaccine distribution (OR of interaction: 232 0.72, 95% CI: 0.52-0.99, p-value=0.044).

233







239 Discussion

240

In our DCE conducted online in six EU countries, we found widespread global solidarity and 241 242 support for a more equitable distribution of COVID-19 vaccines between the Global North and 243 South. Our results point to vaccine allocation preferences that are largely driven by the assessed 244 vulnerability of possible recipients, irrespective of whether the recipient lives in the 245 respondents' own country or in the Global South. Similar to their prioritisation preferences within a country, our respondents - who are themselves not yet vaccinated against COVID-19 246 247 but do favour vaccination – appear to rely upon the same solidarity considerations when 248 vaccines are distributed between countries. For example, they choose the candidate with the 249 higher mortality risk over the candidate with the same nationality. In addition, we find that in 250 a situation of vaccine scarcity and all else being equal, respondents from Spain, Italy, France 251 and Sweden would prefer to allocate the vaccine to a person living in a country in the Global South with a worse health care system, as opposed to a person living in their own country of 252 253 residence. We thus confirm the findings of studies of citizens' distributional preferences, 254 which revealed largely positive attitudes towards vaccine donations to poorer countries in the 255 context of other pandemics(Kumar et al., 2012; Ritvo et al., 2013) and showed in experimental 256 games that individuals follow egalitarian motives in their own decisions, (Dawes et al., 2007) 257 and are even willing to punish third parties for inegalitarian behaviour. (Fehr and Gächter, 2002) 258 Yet, we go beyond previous studies by showing that such support for allocating vaccines to 259 low-income countries with low healthcare system capacity holds across European countries 260 from Spain to Sweden, even among respondents who had themselves not yet gotten vaccinated, 261 and in the context of a pandemic with truly global reach, which by the time when we conducted 262 our experiments had lasted for well more than a year.

At the same time, our findings were inconclusive for Polish respondents and diverged for the German DCE: German survey participants were significantly less willing to allocate the COVID-19 vaccine to a person living in the Global South than to a person living in their own country, thus revealing preferences consistent with vaccine nationalism.

268

269 There are several possible explanations for the strikingly contrasting findings in Germany. 270 First, studies have repeatedly found in-group bias (or here: national bias) in distributional 271 preferences.(Bernhard et al., 2006; Reese et al., 2012; Yudkin et al., 2016) Such in-group bias 272 might explain why German respondents appear willing to allocate the COVID-19 vaccines to 273 more vulnerable candidates (e.g., those with higher COVID-19 risks) within their own country 274 but not to candidates living in the Global South, if German participants had more nationalistic 275 preferences, lower altruism, or less pro-social attitudes than participants from the other five 276 countries. We lack the data to test this possible explanation directly, but it seem unlikely: 277 several cross-country analyses investigating nationalism, patriotism, and xenophobia have 278 found German citizens to be among the least nationalistic in Europe. (Coenders et al., 2021; 279 Lubbers and Coenders, 2017) German citizens also do not generally appear to be outliers 280 among their European peers in terms of altruism or similar pro-sociality variables. (Fehr et al., 281 2021)

282

Second, respondents might have been influenced by heterogeneities in the pandemic situation across countries. In Germany, our experiment was implemented as the third pandemic wave peaked, whereas in the other countries, our DCEs were launched two months later, during a phase of relatively low daily case numbers. German respondents might therefore have felt a greater urgency about having faster access to vaccination – though our data does not show

evidence of a substantially higher reported COVID-19 threat perception among Germanrespondents (see Table S10 and Figure S4).

290

291 Third, the findings could be a function of the differences in the timing of the surveys relative 292 to the progress of national vaccination campaigns. A recent survey experiment found that 293 individuals with a higher perceived rank in the global income distribution feel stronger pressure 294 to donate.(Fehr et al., 2021) Extrapolating this dynamic to the context of our study, we might 295 expect to see a higher individual inclination for vaccine donations in countries where the 296 (perceived) vaccination rate is high by international standards. When the survey was fielded in 297 Italy, France, Spain, Poland, and Sweden, the vaccination rate in those countries exceeded 50% 298 (30%) for first (second) doses whereas in Germany it was only at 25% (8%) (see Table S9). 299 This difference in domestic conditions may have affected the perceived scarcity of the 300 COVID-19 vaccines between countries and the normative assessment thereof.

301

302 A number of limitations are worth noting. First, participants' preferences may partly be driven 303 by cross-country variation in (1) COVID-19 infection and mortality rates, (2) COVID-19 304 vaccination rates, and (3) the pandemic trajectory over time. Our analyses did not allow for any 305 in-depth investigation of these factors. Second, on an individual level, there may be additional 306 characteristics that explain approval or rejection of COVID-19 vaccine donations but were not 307 captured in the survey, including (1) nationalistic attitudes, (2) altruistic preferences or 308 (3) migration background. Third, our analysis points to a number of predictors of variation. 309 However, they are not susceptible to experimental manipulation and should therefore not be 310 interpreted as causal. Fourth, at the country level (except in Germany), we were not able to 311 achieve our initial target sample sizes due to budget constraints. Thus, we likely only have adequate statistical power in the pooled analysis. Lastly and relatedly, sample sizes varied 312

across countries and statistical power was higher in the German survey than in the other five
surveys. However, since we find statistically significant effects of the main attributes in all
countries except from Poland, lack of statistical power might have been less of a concern.

316

317 Policymakers and global health scholars have condemned the unequitable distribution of 318 COVID-19 vaccines between highand low-income countries as "vaccine 319 apartheid".(Gonsalves and Yamey, 2021; Harman et al., 2021) Still, the World Health 320 Organisation's call for a moratorium on COVID-19 booster vaccinations in high-income 321 countries in favour of prioritising first dose vaccinations in low-income countries went 322 unheeded, at least in part out of a sense that donating vaccines to countries in the Global South 323 lacks popular support and might even subject the government to electoral punishment.(Krause 324 et al., 2021) The emergence of the new Omicron variant – and fears of potential future variants 325 - emphasises once again the transboundary nature of the COVID-19 pandemic. 326 Acknowledging this, governments in high-income countries should discard mitigation 327 strategies that are guided by the premise of vaccine nationalism. (Vanhuysse et al., 2021) 328 Findings from our study suggest that governments of European countries can rely on solid 329 public approval for a more equitable vaccine distribution – especially among female, younger 330 and more educated citizens. Public support for vaccine donations to the Global South may 331 further increase once the specific COVID-19 risk groups have received their booster 332 vaccination. More effective international policy initiatives to ensure efficient, adequate, and 333 timely COVID-19 vaccine transfers to low-income countries are urgently needed.

335 Materials and Methods

336 *Study Sample*

We conducted an online survey experiment in six EU countries: France, Germany, Italy, 337 338 Poland, Spain, and Sweden. The German survey was launched at the height of the third wave 339 in April 2021; the other five surveys were carried out in June 2021, coinciding with a phase of 340 low case numbers in each country (see Figure S1). In each country, we recruited respondents 341 aged 18 years and older, drawing on online panels of the survey provider *Bilendi-Respondi*. 342 We sampled participants based on quotas that were matched to the census population of each 343 target country in terms of (1) gender, (2) age, (3) education, and (4) geographic location (e.g., 344 state or province within each country) (see Table S1 for the census statistics of the sampled 345 countries). Participants were given an individual link to the survey, where they first received 346 information about the study's purpose, data protection regulations, and voluntary participation. After completing the survey, participants received a voucher worth three to five Euros, which 347 348 was distributed by the survey company.

349 Survey Experiment

350

351 Discrete choice experiments (DCEs) are used to measure the relative importance of different 352 characteristics that respondents weigh against each other when making certain choices.(Mangham et al., 2009) DCEs have emerged from the theoretical tradition of random 353 354 utility theory and are based on the assumption that respondents express their preferences by 355 choosing the alternative associated with the highest individual benefits or utility.(Hall et al., 356 2004) DCEs have advantages over other stated preference techniques, such as ranking or rating 357 exercises, because they (i) more closely mimic real-world choice scenarios, (ii) reduce the 358 cognitive complexity for respondents, and (iii) can elicit implicit preferences.(Mangham et al., 2009) 359

360

361 We used the DCE methodology to elicit participants' preferences on the allocation of a 362 COVID-19 vaccine dose to a person in the Global North or to a person in the Global South. 363 We presented eight different choice sets and asked respondents to choose whether Person A or 364 Person B should receive the COVID-19 vaccine first. Respondents were told that the other 365 candidate of each pair would have to wait substantially longer to receive their first vaccine 366 dose. In each of the eight choice sets, one candidate was described as living in the country of 367 residence of the respondent -i.e. a high-income country with high healthcare system capacity, 368 and the other candidate was described as living in a low-income country with a low healthcare 369 system capacity. The healthcare system capacity was explicitly mentioned in the two candidate 370 profiles. Across choice sets, candidates' characteristics varied along three additional attributes, 371 namely (1) age (20; 40; 60; 80 years), (2) individual COVID-19 mortality risk due to 372 comorbidity and/or lifestyle (no increased risk; increased risk; strongly increased risk), and (3) 373 employment status (not employed; employed and guaranteed income; employed and income 374 losses due to COVID-19 restrictions; employed in essential services).

375

The specific combination of candidate profiles in the eight choice sets, i.e., the experimental design (presented in Table 4) was selected for statistical efficiency (referred to as "Defficiency"), which is accomplished by minimising the asymptotic variance-covariance matrix of the parameter estimates (based on an algorithm implemented in the software Ngene).(Reed Johnson et al., 2013) A sample choice situation as presented to respondents in the online survey, along with further technical information, is shown in Figure S2 and notes.

ົ	О	\mathbf{r}
J	О	J
_	_	_

389

Table 4. Full list of choice sets of the DCE

Choice	Age in	COVID-19 mortality risk	Employment status	Country of residence and
set	years			healthcare system capacity
1	40	No increased risk due to	Not employed	[Respondents' country of residence],
Person A		comorbidity and/or lifestyle		with high healthcare system capacity
1	40	Strongly increased risk due to	Employed and guaranteed	Low-income country,
Person B		comorbidity and/or lifestyle	income	with poor healthcare system capacity)
2	60	Strongly increased risk due to	Employed and guaranteed	[Respondents' country of residence],
Person		comorbidity and/or lifestyle	income	with high healthcare system capacity
Α				
2	60	No increased risk due to	Employed in essential	Low-income country,
Person B		comorbidity and/or lifestyle	services	with poor healthcare system capacity)
3	60	Increased risk due to	Employed and income losses	[Respondents' country of residence],
Person		comorbidity and/or lifestyle	due to COVID-19 restrictions	with high healthcare system capacity
А				
3	80	Increased risk due to	Not employed	Low-income country,
Person B		comorbidity and/or lifestyle		with poor healthcare system capacity
4	20	Increased risk due to	Employed in essential	Low-income country,
Person		comorbidity and/or lifestyle	services	with poor healthcare system capacity
Α				
4	40	No increased risk due to	Employed and income losses	[Respondents' country of residence],
Person B		comorbidity and/or lifestyle	due to COVID-19 restrictions	with high healthcare system capacity
5	40	No increased risk due to	Employed in essential	[Respondents' country of residence],
Person		comorbidity and/or lifestyle	services	with high healthcare system capacity
А				
5	20	Increased risk due to	Not employed	Low-income country,
Person B		comorbidity and/or lifestyle		with poor healthcare system capacity
6	20	Strongly increased risk due to	Employed and income losses	Low-income country,
Person		comorbidity and/or lifestyle	due to COVID-19 restrictions	with poor healthcare system capacity
Α				
6	20	No increased risk due to	Employed and guaranteed	[Respondents' country of residence],
Person B		comorbidity and/or lifestyle	income	with high healthcare system capacity
7	80	Increased risk due to	Not employed	Low-income country,
Person		comorbidity and/or lifestyle		with poor healthcare system capacity
Α				
7	60	Increased risk due to	Employed and income losses	[Respondents' country of residence],
Person B		comorbidity and/or lifestyle	due to COVID-19 restrictions	with high healthcare system capacity
8	40	No increased risk due to	Employed and guaranteed	Low-income country,
Person		comorbidity and/or lifestyle	income	with poor healthcare system capacity
А				
8	40	Strongly increased risk due to	Employed in essential	[Respondents' country of residence],
Person B		comorbidity and/or lifestyle	services	with high healthcare system capacity

384 Notes: [Respondents' country of residence] was differed depending on the respective country the
385 survey was fielded in, e.g., in the German sample, this attribute level was 'Germany, with high
386 healthcare system capacity'. The design was determined with a built-in constraint for the attributes
387 Age and Employment status in order to avoid implausible combinations (specifically, an age of 80
388 was always combined with not being employed.

Participants were only eligible to participate in the survey experiment if they (1) had not yet been vaccinated against COVID-19 at the time of the survey and (2) indicated that they were willing to get vaccinated. We employed these two criteria to elicit prioritisation preferences on how to distribute scarce COVID-19 vaccine doses among individuals who perceived the vaccine as beneficial *and* were themselves still waiting to receive their first dose. Thus, the

395 decisions of participants in the survey experiment might to a larger extent be informed by the 396 fear/worry of having to sacrifice their own chances of getting a vaccine.

397

398 Power calculations for the discrete choice experiment indicated a desired sample size 399 of n=2,061 respondents per country.(de Bekker-Grob et al., 2015) However, the rapidly 400 evolving pandemic situation in combination with conditional eligibility on vaccination status 401 (see above) only allowed us to reach the required sample size in Germany due to the earlier 402 timing of the data collection. Sample sizes in the remaining countries ranged from 670 in 403 Poland to 925 in Spain, resulting in a total sample size of 6,030 eligible responses.

404

Heterogeneity Variables 405

406 Similar to previous studies, (Duch et al., 2021; Persad et al., 2021) we examined the effect of 407 the attribute 'Country of residence' for heterogeneity in terms of respondents' socioeconomic 408 characteristics. Specifically, we assessed whether respondents' (i) gender, (ii) age, (iii) 409 education, (iv) individual COVID-19 risk status, (v) COVID-19 threat perception, and (vi) 410 employment status predicted differences in their allocation choices. Considering the limited 411 statistical power within countries, the heterogeneity analysis was conducted with the pooled 412 sample.

413 Statistical Analyses

414

415 The empirical analysis comprised three steps. First, we estimated the main effects model for each country separately to assess the impact of the four candidate attributes (country of 416 417 residence, age, COVID-19 mortality risk, employment status) on the probability of choosing a specific candidate. For each of the six countries, we estimated a conditional logit model by 418 419 regressing the respondents' allocation choice on the attribute levels of the candidate. Second, 420 we examined heterogeneity in the effect of the country of residence attribute by adding

421 interaction terms between country of residence and heterogeneity variables to the above

- 422 regression. A pre-analysis plan along with justifications of any deviations thereof is accessible
- 423 via https://osf.io/72jrg/.

424 Ethical Approval

425

- 426 The study received approvals from the ethics committees of the medical faculty at the Technical
- 427 University of Munich (TUM, IRB 227/20 S) and the ethics board at the University of Trento
- 428 (Trento, IRB 2021-027).

429

430 Acknowledgements

We thank everyone who helped with translating: Walter Osika, Jocelyn Raude, Jonathan Garcia
Fuentes, Anna Glyk, and Kathrin and Michal Bartoszewski. This project was funded by the
European Union's Horizon 2020 research and innovation programme under grant agreement
No 101016233 PERISCOPE). We are grateful for helpful comments on the analysis and
interpretation made by Philipp Lergetporer, Michael Kurschilgen and Abu Siddique.

436

437 Competing interests

438 The authors have no competing interests to declare.

439 Author contributions

GAV, TB, and JIS acquired funding for this research study. JIS, HS and TB conceptualised and led the study and developed the pre-analysis plan. JIS, GAV and HS oversaw and managed the data collection. JIS and HS merged and cleaned the data, and HS conducted the data analyses and data visualisations. JIS, HS, TB, and GAV contributed to the interpretation of the quantitative findings. JIS and HS drafted the first version of the manuscript and all authors provided substantial revisions and feedback. We confirm that all authors have read and approved the final version of the manuscript.

447

448 Data availability statement

449 A pre-analysis plan along with justifications of any deviations thereof is accessible via the

450 Open Science Framework website: <u>https://osf.io/72jrq/</u>. All data and code will be shared via

the same website.

452 References

л	Б	2
+	J	J

453	
454	Bernhard, H., Fischbacher, U., Fehr, E., 2006. Parochial altruism in humans. Nature 442,
455	912–915. https://doi.org/10.1038/nature04981
456	Clarke, P.M., Roope, L.S.J., Loewen, P.J., Bonnefon, JF., Melegaro, A., Friedman, J.,
457	Violato, M., Barnett, A., Duch, R., 2021. Public opinion on global rollout of COVID-
458	19 vaccines. Nat Med 27, 935–936. https://doi.org/10.1038/s41591-021-01322-9
459	Coenders, M., Lubbers, M., Scheepers, P., 2021. Nationalism in Europe: Trends and Cross-
460	national Differences in Public Opinion. European Review 29, 484–496.
461	https://doi.org/10.1017/S1062798720000526
462	Dawes, C.T., Fowler, J.H., Johnson, T., McElreath, R., Smirnov, O., 2007. Egalitarian
463	motives in humans. Nature 446, 794–796.
464	de Bekker-Grob, E.W., Donkers, B., Jonker, M.F., Stolk, E.A., 2015. Sample Size
465	Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide.
466	Patient 8, 373–384. https://doi.org/10.1007/s40271-015-0118-z
467	Duch, R., Roope, L.S.J., Violato, M., Becerra, M.F., Robinson, T.S., Bonnefon, JF.,
468	Friedman, J., Loewen, P.J., Mamidi, P., Melegaro, A., Blanco, M., Vargas, J., Seither,
469	J., Candio, P., Cruz, A.G., Hua, X., Barnett, A., Clarke, P.M., 2021. Citizens from 13
470	countries share similar preferences for COVID-19 vaccine allocation priorities. PNAS
471	118. https://doi.org/10.1073/pnas.2026382118
472	Fehr, D., Mollerstrom, J., Perez-Truglia, R., 2021. Your Place in the World - Relative Income
473	and Global Inequality (SSRN Scholarly Paper No. ID 3832475). Social Science
474	Research Network, Rochester, NY. https://doi.org/10.2139/ssrn.3832475
475	Fehr, E., Gachter, S., 2002. Altruistic punishment in humans. Nature 415, 137–140.
476	1000000000000000000000000000000000000
477	Godiee, F., 2021. Vaccines should not be the preserve of rich countries. BMJ 3/4, n2044.
478	nups://doi.org/10.1150/dnj.n2044
479	Allocation of a Vaccine for Coronavirus Disease 2010, JAMA Natur Open 2
400	Anocation of a vacche for Coronavirus Disease 2019. JANA Netw Open 5, e2023020 https://doi.org/10.1001/jamanetworkonen.2020.23020
401	Gonsalves G. Vamey G. 2021 The covid-19 vaccine patent waiver: a crucial step towards
483	a "people's vaccine" BMI 373 n1249 https://doi.org/10.1136/bmi.n1249
484	Guidry LPD Perrin P.B. Laestadius I.I. Vraga F.K. Miller C.A. Fuemmeler B.F.
485	Burton C W Ryan M Carlyle K F 2021 U S public support for COVID-19
486	vaccine donation to low- and middle-income countries during the COVID-19
487	pandemic. Vaccine 39. 2452–2457. https://doi.org/10.1016/i.vaccine.2021.03.027
488	Hafner, M., Yerushalmi, E., Fays, C., Dufresne, E., Van Stolk, C., 2020, COVID-19 and the
489	cost of vaccine nationalism. RAND Corporation.
490	Hall, J., Viney, R., Haas, M., Louviere, J., 2004. Using stated preference discrete choice
491	modeling to evaluate health care programs. Journal of Business Research 57, 1026–
492	1032.
493	Harman, S., Erfani, P., Goronga, T., Hickel, J., Morse, M., Richardson, E.T., 2021. Global
494	vaccine equity demands reparative justice — not charity. BMJ Global Health 6,
495	e006504. https://doi.org/10.1136/bmjgh-2021-006504
496	Herzog, L.M., Norheim, O.F., Emanuel, E.J., McCoy, M.S., 2021. Covax must go beyond
497	proportional allocation of covid vaccines to ensure fair and equitable access. BMJ
498	372, m4853. https://doi.org/10.1136/bmj.m4853

- Katz, I.T., Weintraub, R., Bekker, L.-G., Brandt, A.M., 2021. From Vaccine Nationalism to
 Vaccine Equity Finding a Path Forward. N Engl J Med 384, 1281–1283.
 https://doi.org/10.1056/NEJMp2103614
- Kim, H., 2021. We need people's WHO to solve vaccine inequity, and we need it now. BMJ
 Global Health 6, e006598. https://doi.org/10.1136/bmjgh-2021-006598
- Klumpp, M., Monfared, I.G., Vollmer, S., 2021. To share or not to share What the general
 public thinks about global COVID-19 vaccine distribution.
 https://doi.org/10.1101/2021.08.16.21262116
- 507 Knotz, C.M., Gandenberger, M.K., Fossati, F., Bonoli, G., 2021. Popular Attitudes Toward
 508 the Distribution of Vaccines Against COVID-19: The Swiss Case. Swiss Political
 509 Science Review 27, 297–310. https://doi.org/10.1111/spsr.12461
- Krause, P.R., Fleming, T.R., Peto, R., Longini, I.M., Figueroa, J.P., Sterne, J.A.C., Cravioto,
 A., Rees, H., Higgins, J.P.T., Boutron, I., Pan, H., Gruber, M.F., Arora, N., Kazi, F.,
 Gaspar, R., Swaminathan, S., Ryan, M.J., Henao-Restrepo, A.-M., 2021.
 Considerations in boosting COVID-19 vaccine immune responses. The Lancet 398,
- 514 1377–1380. https://doi.org/10.1016/S0140-6736(21)02046-8
 515 Kumar, S., Quinn, S.C., Kim, K.H., Hilyard, K.M., 2012. US Public Support for Vaccine
- 515 Kullar, S., Qullin, S.C., Klin, K.H., Hilyard, K.M., 2012. OS Public Support for Vaccine
 516 Donation to Poorer Countries in the 2009 H1N1 Pandemic. PLOS ONE 7, e33025.
 517 https://doi.org/10.1371/journal.pone.0033025
- Lubbers, M., Coenders, M., 2017. Nationalistic attitudes and voting for the radical right in
 Europe. European Union Politics 18, 98–118.
 https://doi.org/10.1177/1465116516678932
- Luyten, J., Tubeuf, S., Kessels, R., 2020. Who should get it first? Public preferences for
 distributing a COVID-19 vaccine. Covid Economics, Vetted and Real-Time Papers
 57.
- Mangham, L.J., Hanson, K., McPake, B., 2009. How to do (or not to do) ... Designing a
 discrete choice experiment for application in a low-income country. Health Policy
 Plan 24, 151–158. https://doi.org/10.1093/heapol/czn047
- Padma, T.V., 2021. COVID vaccines to reach poorest countries in 2023 despite recent
 pledges. Nature 595, 342–343. https://doi.org/10.1038/d41586-021-01762-w
- Persad, G., Emanuel, E.J., Sangenito, S., Glickman, A., Phillips, S., Largent, E.A., 2021.
 Public Perspectives on COVID-19 Vaccine Prioritization. JAMA Netw Open 4, e217943. https://doi.org/10.1001/jamanetworkopen.2021.7943
- Reed Johnson, F., Lancsar, E., Marshall, D., Kilambi, V., Mühlbacher, A., Regier, D.A.,
 Bresnahan, B.W., Kanninen, B., Bridges, J.F.P., 2013. Constructing experimental
 designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis
 Experimental Design Good Research Practices Task Force. Value Health 16, 3–13.
 https://doi.org/10.1016/j.jval.2012.08.2223
- Reese, G., Berthold, A., Steffens, M.C., 2012. We Are the World—and They Are Not:
 Prototypicality for the World Community, Legitimacy, and Responses to Global Inequality. Political Psychology 33, 683–700.
- Reeskens, T., Roosma, F., Wanders, E., 2021. The perceived deservingness of COVID-19
 healthcare in the Netherlands: a conjoint experiment on priority access to intensive
 care and vaccination. BMC Public Health 21, 1–8. https://doi.org/10.1186/s12889021-10488-3
- Ritvo, P., Perez, D.F., Wilson, K., Gibson, J.L., Guglietti, C.L., Tracy, C.S., Bensimon, C.M.,
 Upshur, R.E., University of Toronto Joint Centre for Bioethics Pandemic Ethics
 Working Group, 2013. Canadian national surveys on pandemic influenza
 preparations: pre-pandemic and peri-pandemic findings. BMC Public Health 13, 271.
 https://doi.org/10.1186/1471-2458-13-271

549	Saad-Roy, C.M., Morris, S.E., Metcalf, C.J.E., Mina, M.J., Baker, R.E., Farrar, J., Holmes,
550	E.C., Pybus, O.G., Graham, A.L., Levin, S.A., Grenfell, B.T., Wagner, C.E., 2021.
551	Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing
552	regimes. Science 372, 363–370. https://doi.org/10.1126/science.abg8663
553	Sprengholz, P., Korn, L., Eitze, S., Betsch, C., 2021. Allocation of COVID-19 vaccination:
554	when public prioritisation preferences differ from official regulations. J Med Ethics
555	medethics-2021-107339. https://doi.org/10.1136/medethics-2021-107339
556	Telenti, A., Arvin, A., Corey, L., Corti, D., Diamond, M.S., García-Sastre, A., Garry, R.F.,
557	Holmes, E.C., Pang, P.S., Virgin, H.W., 2021. After the pandemic: perspectives on
558	the future trajectory of COVID-19. Nature 596, 495–504.
559	https://doi.org/10.1038/s41586-021-03792-w
560	UN Secretary General, 2021. Secretary-General's address to the 76th Session of the UN
561	General Assembly United Nations Secretary-General [WWW Document]. URL
562	https://www.un.org/sg/en/node/259283 (accessed 12.8.21).
563	UN Secretary General, 2021b. A global pandemic requires a world effort to end it – none of
564	us will be safe until everyone is safe [WWW Document]. URL
565	https://www.who.int/news-room/commentaries/detail/a-global-pandemic-requires-a-
566	world-effort-to-end-it-none-of-us-will-be-safe-until-everyone-is-safe (accessed
567	12.8.21).
568	van Oosterhout, C., Hall, N., Ly, H., Tyler, K.M., 2021. COVID-19 evolution during the
569	pandemic - Implications of new SARS-CoV-2 variants on disease control and public
570	health policies. Virulence 12, 507–508.
571	https://doi.org/10.1080/21505594.2021.1877066
572	Vanhuysse, P., Jankowski, M., Tepe, M., 2021. Vaccine alliance building blocks: a conjoint
573	experiment on popular support for international COVID-19 cooperation formats.
574	Policy Sci 1-14. https://doi.org/10.1007/s11077-021-09435-1
575	Wagner, C.E., Saad-Roy, C.M., Morris, S.E., Baker, R.E., Mina, M.J., Farrar, J., Holmes,
576	E.C., Pybus, O.G., Graham, A.L., Emanuel, E.J., Levin, S.A., Metcalf, C.J.E.,
577	Grenfell, B.T., 2021. Vaccine nationalism and the dynamics and control of SARS-
578	CoV-2. Science 373, eabj7364. https://doi.org/10.1126/science.abj7364
579	Wouters, O.J., Shadlen, K.C., Salcher-Konrad, M., Pollard, A.J., Larson, H.J.,
580	Teerawattananon, Y., Jit, M., 2021. Challenges in ensuring global access to COVID-
581	19 vaccines: production, affordability, allocation, and deployment. Lancet 397, 1023-
582	1034. https://doi.org/10.1016/S0140-6736(21)00306-8
583	Yudkin, D.A., Rothmund, T., Twardawski, M., Thalla, N., Van Bavel, J.J., 2016. Reflexive
584	intergroup bias in third-party punishment. J Exp Psychol Gen 145, 1448–1459.
585	https://doi.org/10.1037/xge0000190
586	
587	